Chemical pharmaceutical consists mainly of
chemical drug preparation and active pharmaceutical ingredient (API), and the
gross margin of chemical drug preparation industry is generally higher than
that of the API over the same period. In 2013, China chemical drug preparation
industry and and China API industry recorded revenue of RMB 573.1 billion and
RMB 382 billion, with gross margin of 35%-40% and 20%, respectively.
Browse Full Report With TOC: http://www.marketresearchreports.biz/analysis-details/china-chemical-pharmaceutical-industry-report-2013-2016
China is a big
producer of chemical APIs, capable of producing about 1,600 varieties of APIs.
China ranks first worldwide in output of several bulk APIs including
penicillins, vitamins and antipyretic analgesics, and holds a significant
share of the featured APIs like statins, prils, sartans in the world. China
produced 2.709 million tons of chemical APIs in 2013.
Although China is the
world's leading chemical APIs supply region, the concentration of China
chemical APIs industry is rather low due to numerous categories of APIs and
limited overall strength of domestic enterprises, which occupy an important
place only in single or a few categories of pharmaceuticals market. In
addition, under the pressure of both environmental protection and industrial
upgrading, many large APIs companies in the country are transforming into drug
preparation companies through means such as R&D and acquisitions.
North China
Pharmaceutical Group Corp. (NCPC) and Northeast Pharmaceutical Group Co., Ltd.
are major suppliers of antibiotic and VC APIs in China, with supply of VS
reaching around 20,000 tons each. In 2013, the two companies’ total revenue
from APIs and their revenue from drug preparation business reached RMB 5.695
billion and RMB 3.871 billion, respectively.
Zhejiang Medicine
Co., Ltd. and Zhejiang NHU Co., Ltd. are the leading manufacturers of VE
products around the globe, with raw materials (vital ingredients for the
production of VE are limited raw materials: isophytol and
trimethylhydroquinone) for VE being produced by themselves. However, the two
companies’ development is constrained due to a weak global demand for VE, of
which Zhejiang Medicine reported revenue of RMB 4.915 billion from
pharmaceutical business (APIs+ preparation), down 6.3% year on year.
Zhejiang Hisun
Pharmaceutical Co., Ltd. and Zhejiang Huahai Pharmaceuticals Co., Ltd. are the
key suppliers of featured APIs in China, of which the former specializes in
antineoplastic and cardiovascular products, and the latter, which obtains
three certificates from EDQM in 2013, is a major global supplier of prils and
sartans APIs. In 2013, the two companies’ total revenues from APIs and drug
preparation business were RMB 3.226 billion and RMB 2.272 billion, rising by
19.5% and 14.7% from the previous year, respectively.
Zhejiang Xianju
Pharmaceutical Co., Ltd. and Tianjin Tianyao Pharmaceuticals Co., Ltd. are the
leading suppliers of hormone APIs, of which the former has been aggressively
expanding into downstream drug preparation business. In the context of
stricter environmental standards and rising costs of raw materials, developing
the downstream will undoubtedly ensure competitiveness of the company.
|
Office:
United States
|
|
State Tower
90 State Street, Suite 700 Albany, NY 12207 United States |
No comments:
Post a Comment